AB Science Reports 2025 Financial Results and Clinical Developments

AB Science announced a reduced operating loss of €3.8 million as of December 31, 2025, reflecting a 38% decrease year-on-year. The company ended the year with a cash position of €10.2 million, plus an additional €3.2 million from an April 2026 private placement.

Diverse clinical advancements in 2025 focused on masitinib, notably in amyotrophic lateral sclerosis (ALS), and AB8939 in acute myeloid leukemia (AML). Key events included European approvals for masitinib's Phase 3 ALS trial and the initiation of AB8939's third stage in AML trials.

The year also saw a strategic suspension of certain clinical trials in Europe to realign resources towards masitinib Phase 3 and AB8939 programs, coinciding with a voluntary halt in new patient recruitment for negotiations and regulatory discussions.

Financially, revenues from veterinary medicine sales were up by 10% from the previous year, with a recorded operating profit of €639 thousand, a substantial turnaround from the previous year’s losses.